{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:47:31Z","timestamp":1790887651810,"version":"4.1.0"},"reference-count":62,"publisher":"The Endocrine Society","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12,1]]},"abstract":"<jats:p>Circulating levels of the pancreatic \u03b2-cell peptide hormone amylin and the gut peptide PYY[3\u201336] increase after nutrient ingestion. Both have been implicated as short-term signals of meal termination with anorexigenic and weight-reducing effects. However, their combined effects are unknown. We report that the combination of amylin and PYY[3\u201336] elicited greater anorexigenic and weight-reducing effects than either peptide alone. In high-fat-fed rats, a single ip injection of amylin (10 \u03bcg\/kg) plus PYY[3\u201336] (1000 \u03bcg\/kg) reduced food intake for 24 h (P &amp;lt; 0.05 vs. vehicle), whereas the anorexigenic effects of either PYY[3\u201336] or amylin alone began to diminish 6 h after injection. These anorexigenic effects were dissociable from changes in locomotor activity. Subcutaneous infusion of amylin plus PYY[3\u201336] for 14 d suppressed food intake and body weight to a greater extent than either agent alone in both rat and mouse diet-induced obesity (DIO) models (P &amp;lt; 0.05). In DIO-prone rats, 24-h metabolic rate was maintained despite weight loss, and amylin plus PYY[3\u201336] (but not monotherapy) increased 24-h fat oxidation (P &amp;lt; 0.05 vs. vehicle). Finally, a 4 \u00d7 3 factorial design was used to formally describe the interaction between amylin and PYY[3\u201336]. DIO-prone rats were treated with amylin (0, 4, 20, and 100 \u03bcg\/kg\u00b7d) and PYY[3\u201336] (0, 200, 400 \u03bcg\/kg\u00b7d) alone and in combination for 14 d. Statistical analyses revealed that food intake suppression with amylin plus PYY[3\u201336] treatment was synergistic, whereas body weight reduction was additive. Collectively, these observations highlight the importance of studying peptide hormones in combination and suggest that integrated neurohormonal approaches may hold promise as treatments for obesity.<\/jats:p>","DOI":"10.1210\/en.2007-0898","type":"journal-article","created":{"date-parts":[[2007,8,31]],"date-time":"2007-08-31T00:44:10Z","timestamp":1188521050000},"page":"6054-6061","source":"Crossref","is-referenced-by-count":68,"title":["Combination Therapy with Amylin and Peptide YY[3\u201336] in Obese Rodents: Anorexigenic Synergy and Weight Loss Additivity"],"prefix":"10.1210","volume":"148","author":[{"given":"Jonathan D.","family":"Roth","sequence":"first","affiliation":[{"name":"Amylin Pharmaceuticals, Inc., San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Coffey","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Inc., San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn M.","family":"Jodka","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Inc., San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Maier","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Inc., San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Athanacio","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Inc., San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine M.","family":"Mack","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Inc., San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weyer","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Inc., San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Parkes","sequence":"additional","affiliation":[{"name":"Amylin Pharmaceuticals, Inc., San Diego, California 92121"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"2020071614175597700_R1","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/0140-6736(92)90785-2","article-title":"Amylin concentrations and glucose control.","volume":"339","author":"Koda","year":"1992","journal-title":"Lancet"},{"key":"2020071614175597700_R2","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.ijo.0801664","article-title":"The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema\/nucleus of the solitary tract (AP\/NTS) lesioned rats.","volume":"25","author":"Lutz","year":"2001","journal-title":"Int J Obes Relat Metab Disord"},{"key":"2020071614175597700_R3","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.physbeh.2004.01.006","article-title":"Infusion of the amylin antagonist AC 187 into the area postrema increases food intake in rats.","volume":"81","author":"Mollet","year":"2004","journal-title":"Physiol Behav"},{"key":"2020071614175597700_R4","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0196-9781(97)00292-1","article-title":"Lesion of the area postrema nucleus of the solitary tract (AP\/NTS) attenuates the anorectic effects of amylin and calcitonin gene-related peptide (CGRP) in rats.","volume":"19","author":"Lutz","year":"1998","journal-title":"Peptides"},{"key":"2020071614175597700_R5","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1055\/s-2007-978590","article-title":"Amylin and insulin interact to reduce food intake in rats.","volume":"32","author":"Rushing","year":"2000","journal-title":"Horm Metab Res"},{"key":"2020071614175597700_R6","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1210\/endo.141.2.7378","article-title":"Amylin: a novel action in the brain to reduce body weight.","volume":"141","author":"Rushing","year":"2000","journal-title":"Endocrinology"},{"key":"2020071614175597700_R7","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.1210\/en.2006-0393","article-title":"Anti-obesity effects of the \u03b2-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure and gene expression.","volume":"147","author":"Roth","year":"2006","journal-title":"Endocrinology"},{"key":"2020071614175597700_R8","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1007\/s00125-005-1732-4","article-title":"Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes.","volume":"48","author":"Chapman","year":"2005","journal-title":"Diabetologia"},{"key":"2020071614175597700_R9","doi-asserted-by":"crossref","first-page":"E620","DOI":"10.1152\/ajpendo.00217.2007","article-title":"Pramlintide treatment reduces 24-h caloric intake and meal sizes and improves control of eating in obese subjects: a 6-wk translational research study","volume":"293","author":"Smith","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"Suppl 1","key":"2020071614175597700_R10","first-page":"21","article-title":"Safety, dose-tolerance, and weight-related effects of pramlintide in obese subjects with or without type 2 diabetes","volume":"6","author":"Weyer","year":"2005","journal-title":"Obes Rev"},{"key":"2020071614175597700_R11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/oby.2004.76","article-title":"Effect of pramlintide on weight in overweight and obese insulin-treated type 2 diabetes patients.","volume":"12","author":"Hollander","year":"2004","journal-title":"Obes Res"},{"issue":"Suppl 2","key":"2020071614175597700_R12","first-page":"112","article-title":"Pramlintide treatment in obesity elicited progressive weight loss when used with a structured lifestyle intervention program: a randomized controlled trial","volume":"7","author":"Wadden","year":"2006","journal-title":"Obes Rev"},{"issue":"Suppl 1","key":"2020071614175597700_R13","first-page":"A88","article-title":"Sustained weight loss following 1-y pramlintide treatment as an adjunct to lifestyle intervention in obesity","volume":"56","author":"Smith","year":"2007","journal-title":"Diabetes"},{"key":"2020071614175597700_R14","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0196-9781(89)90116-2","article-title":"A new molecular form of PYY: structural characterization of human PYY(3\u201336) and PYY(1\u201336).","volume":"10","author":"Eberlein","year":"1989","journal-title":"Peptides"},{"key":"2020071614175597700_R15","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/0016-5085(85)90211-2","article-title":"Human distribution and release of a putative new gut hormone, peptide YY.","volume":"89","author":"Adrian","year":"1985","journal-title":"Gastroenterology"},{"key":"2020071614175597700_R16","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0167-0115(03)00115-0","article-title":"Cholecystokinin and peptide YY are released by fat in either proximal or distal small intestine in dogs.","volume":"114","author":"Lin","year":"2003","journal-title":"Regul Pept"},{"key":"2020071614175597700_R17","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/nature00887","article-title":"Gut hormone PYY(3\u201336) physiologically inhibits food intake.","volume":"418","author":"Batterham","year":"2002","journal-title":"Nature"},{"key":"2020071614175597700_R18","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.bbrc.2003.10.089","article-title":"Acute effects of PYY(3\u201336) on food intake and hypothalamic neuropeptide expression in the mouse.","volume":"311","author":"Challis","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"2020071614175597700_R19","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1056\/NEJMoa030204","article-title":"Inhibition of food intake in obese subjects by peptide YY3\u201336.","volume":"349","author":"Batterham","year":"2003","journal-title":"N Engl J Med"},{"key":"2020071614175597700_R20","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1053\/j.gastro.2005.09.001","article-title":"Effect of peptide YY3\u201336 on food intake in humans.","volume":"129","author":"Degen","year":"2005","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"2020071614175597700_R21","first-page":"21","article-title":"A phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of rising doses of AC162352 (synthetic human PYY3\u201336) in lean and obese subjects","volume":"6","author":"Lush","year":"2005","journal-title":"Obes Rev"},{"key":"2020071614175597700_R22","first-page":"162","article-title":"A phase 1 study to evaluate the safety, tolerability, and pharmacokinetics of rising doses of AC162352 (synthetic human PYY3\u201336) in lean and obese subjects","author":"Troupin"},{"key":"2020071614175597700_R23","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1210\/jc.2006-1806","article-title":"Efficacy and safety of intranasal peptide YY3\u201336 for weight reduction in obese adults.","volume":"92","author":"Gantz","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2020071614175597700_R24","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJM199503093321001","article-title":"Changes in energy expenditure resulting from altered body weight.","volume":"332","author":"Leibel","year":"1995","journal-title":"N Engl J Med"},{"key":"2020071614175597700_R25","first-page":"R725","article-title":"Selective breeding for diet-induced obesity and resistance in Sprague-Dawley rats","volume":"273","author":"Levin","year":"1997","journal-title":"Am J Physiol"},{"key":"2020071614175597700_R26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.3109\/10915818809014527","article-title":"A statistical approach to the construction and analysis of isobolograms.","volume":"7","author":"Carter","year":"1988","journal-title":"J Am Coll Toxicol"},{"key":"2020071614175597700_R27","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0065-230X(08)60912-4","article-title":"Criteria for analyzing interactions between biologically active agents.","volume":"35","author":"Berenbaum","year":"1981","journal-title":"Adv Cancer Res"},{"key":"2020071614175597700_R28","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1097\/00000542-200006000-00017","article-title":"Response surface model for anesthetic drug interactions.","volume":"92","author":"Minto","year":"2000","journal-title":"Anesthesiology"},{"key":"2020071614175597700_R29","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1128\/AAC.41.10.2159","article-title":"Activities of the human immunodeficiency virus type 1 (HIV-1) protease inhibitor nelfinavir mesylate in combination with reverse transcriptase and protease inhibitors against acute HIV-1 infection in vitro.","volume":"41","author":"Patick","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"2020071614175597700_R30","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0895-7061(96)00323-8","article-title":"Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension.","volume":"10","author":"Pool","year":"1997","journal-title":"Am J Hypertens"},{"key":"2020071614175597700_R31","first-page":"133","article-title":"Review of the application of response surface methodology in the combination therapy of cancer.","volume":"70","author":"Carter Jr","year":"1986","journal-title":"Cancer Treat Rep"},{"key":"2020071614175597700_R32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/0031-9384(94)90076-0","article-title":"Reduction of food intake in rats by intraperitoneal injection of low doses of amylin.","volume":"55","author":"Lutz","year":"1994","journal-title":"Physiol Behav"},{"key":"2020071614175597700_R33","doi-asserted-by":"crossref","first-page":"5120","DOI":"10.1210\/en.2005-0237","article-title":"Peptide YY3\u201336 and glucagon-like peptide-17\u201336 inhibit food intake additively.","volume":"146","author":"Neary","year":"2005","journal-title":"Endocrinology"},{"key":"2020071614175597700_R34","doi-asserted-by":"crossref","first-page":"R39","DOI":"10.1152\/ajpregu.00164.2007","article-title":"Intermittent intraperitoneal infusion of peptide YY(3\u201336) reduces daily food intake and adiposity in obese rats","volume":"293","author":"Chelikani","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2020071614175597700_R35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1172\/JCI30227","article-title":"Gastrointestinal regulation of food intake.","volume":"117","author":"Cummings","year":"2007","journal-title":"J Clin Invest"},{"key":"2020071614175597700_R36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/S0031-9384(98)00110-3","article-title":"Synergy between amylin and cholecystokinin for inhibition of food intake in mice.","volume":"64","author":"Bhavsar","year":"1998","journal-title":"Physiol Behav"},{"key":"2020071614175597700_R37","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1210\/en.2005-0473","article-title":"Peripheral exendin-4 and peptide YY3\u201336 synergistically reduce food intake through different mechanisms in mice.","volume":"146","author":"Talsania","year":"2005","journal-title":"Endocrinology"},{"key":"2020071614175597700_R38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1172\/JCI200522081","article-title":"Leptin action in the forebrain regulates the hindbrain response to satiety signals.","volume":"115","author":"Morton","year":"2005","journal-title":"J Clin Invest"},{"key":"2020071614175597700_R39","doi-asserted-by":"crossref","first-page":"3387","DOI":"10.2337\/db06-0558","article-title":"Leptin regulation of the anorexic response to glucagon-like peptide-1 receptor stimulation.","volume":"55","author":"Williams","year":"2006","journal-title":"Diabetes"},{"key":"2020071614175597700_R40","article-title":"2006 Leptin responsivity restored in leptin-resistant diet-induced obese (DIO) rats: synergistic actions of amylin and leptin for reduction in body weight (BW) and fat","author":"Roth"},{"issue":"Suppl 1","key":"2020071614175597700_R41","first-page":"A72","article-title":"Responsiveness to leptin restored by amylin in diet-induced obese (DIO) rats: magnitude and mechanisms of synergy","volume":"56","author":"Roth","year":"2007","journal-title":"Diabetes"},{"key":"2020071614175597700_R42","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/jn\/136.1.195","article-title":"PYY[3\u201336] administration decreases the respiratory quotient and reduces adiposity in diet-induced obese mice.","volume":"136","author":"Adams","year":"2006","journal-title":"J Nutr"},{"key":"2020071614175597700_R43","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1677\/joe.1.05866","article-title":"Appetite control.","volume":"184","author":"Wynne","year":"2005","journal-title":"J Endocrinol"},{"key":"2020071614175597700_R44","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/0196-9781(92)90057-A","article-title":"Tests of adipsia and conditioned taste aversion following the intrahypothalamic injection of amylin.","volume":"13","author":"Chance","year":"1992","journal-title":"Peptides"},{"key":"2020071614175597700_R45","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0196-9781(02)00022-0","article-title":"Acute 3rd-ventricular amylin infusion potently reduces food intake but does not produce aversive consequences.","volume":"23","author":"Rushing","year":"2002","journal-title":"Peptides"},{"key":"2020071614175597700_R46","first-page":"369","article-title":"Amylin\u2019s inhibitory effect on food intake is not due to malaise in rats.","volume":"44","author":"Naeve","year":"2005","journal-title":"Appetite"},{"key":"2020071614175597700_R47","first-page":"375","article-title":"Dissociation of acute food intake and locomotor activity effects in rats after peripheral treatment with rat amylin.","volume":"44","author":"Roan","year":"2005","journal-title":"Appetite"},{"key":"2020071614175597700_R48","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.cmet.2005.02.003","article-title":"Peripheral administration of PYY(3\u201336) produces conditioned taste aversion in mice.","volume":"1","author":"Halatchev","year":"2005","journal-title":"Cell Metab"},{"key":"2020071614175597700_R49","doi-asserted-by":"crossref","first-page":"3193","DOI":"10.1016\/j.peptides.2006.08.001","article-title":"Dose-dependent effects of peptide YY(3\u201336) on conditioned taste aversion in rats.","volume":"27","author":"Chelikani","year":"2006","journal-title":"Peptides"},{"key":"2020071614175597700_R50","doi-asserted-by":"crossref","first-page":"R367","DOI":"10.1152\/ajpregu.00726.2005","article-title":"PYY(3\u201336) reduces food intake and body weight and improves insulin sensitivity in rodent models of diet-induced obesity","volume":"291","author":"Vrang","year":"2006","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2020071614175597700_R51","doi-asserted-by":"crossref","first-page":"E1062","DOI":"10.1152\/ajpendo.00450.2006","article-title":"Effects of PYY1\u201336 and PYY3\u201336 on appetite, energy intake, energy expenditure, glucose and fat metabolism in obese and lean subjects","volume":"292","author":"Sloth","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071614175597700_R52","doi-asserted-by":"crossref","first-page":"E604","DOI":"10.1152\/ajpendo.00153.2007","article-title":"The effect of subcutaneous injections of PYY1\u201336 and PYY3\u201336 on appetite, ad libitum energy intake and plasma free fatty acids concentration in obese males","volume":"293","author":"Sloth","year":"2007","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2020071614175597700_R53","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0306-4522(94)90388-3","article-title":"In vitro autoradiographic localization of amylin binding sites in rat brain.","volume":"62","author":"Sexton","year":"1994","journal-title":"Neuroscience"},{"key":"2020071614175597700_R54","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/00001756-199603220-00013","article-title":"Comparative autoradiographic distribution of neuropeptide Y Y1 receptors visualized with the Y1 receptor agonist.","volume":"7","author":"Dumont","year":"1996","journal-title":"Neuroreport"},{"key":"2020071614175597700_R55","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S0167-0115(97)01034-3","article-title":"Comparison of Fos induced in rat brain by GLP-1 and amylin.","volume":"71","author":"Rowland","year":"1997","journal-title":"Regul Pept"},{"key":"2020071614175597700_R56","doi-asserted-by":"crossref","first-page":"R114","DOI":"10.1152\/ajpregu.00333.2003","article-title":"The anorectic hormone amylin contributes to feeding-related changes of neuronal activity in key structures of the gut-brain axis","volume":"286","author":"Riediger","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2020071614175597700_R57","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1113\/jphysiol.2003.042036","article-title":"Neuropeptide Y and peptide YY inhibit excitatory synaptic transmission in the rat dorsal motor nucleus of the vagus.","volume":"549","author":"Browning","year":"2003","journal-title":"J Physiol"},{"key":"2020071614175597700_R58","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2982.1997.d01-26.x","article-title":"PYY and NPY: control of gastric motility via action on Y1 and Y2 receptors in the DVC.","volume":"9","author":"Chen","year":"1997","journal-title":"Neurogastroenterol Motil"},{"key":"2020071614175597700_R59","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.peptides.2004.03.003","article-title":"Enhancement of feeding suppression by PYY(3\u201336) in rats with area postrema ablations.","volume":"25","author":"Cox","year":"2004","journal-title":"Peptides"},{"key":"2020071614175597700_R60","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.brainres.2003.10.040","article-title":"Peripheral amylin activates circumventricular organs expressing calcitonin receptor a\/b subtypes and receptor-activity modifying proteins in the rat.","volume":"997","author":"Barth","year":"2004","journal-title":"Brain Res"},{"key":"2020071614175597700_R61","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1389450053174523","article-title":"Peptide YY: a potential therapy for obesity.","volume":"6","author":"Renshaw","year":"2005","journal-title":"Curr Drug Targets"},{"key":"2020071614175597700_R62","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.1073\/pnas.0306931101","article-title":"Mice lacking pro-opiomelanocortin are sensitive to high-fat feeding but respond normally to the acute anorectic effects of peptide-YY3\u201336.","volume":"101","author":"Challis","year":"2004","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/148\/12\/6054\/10727015\/endo6054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/endo\/article-pdf\/148\/12\/6054\/10727015\/endo6054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T01:53:44Z","timestamp":1594950824000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/148\/12\/6054\/2502101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12,1]]},"references-count":62,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2007,12,1]]}},"URL":"https:\/\/doi.org\/10.1210\/en.2007-0898","relation":{},"ISSN":["0013-7227","1945-7170"],"issn-type":[{"value":"0013-7227","type":"print"},{"value":"1945-7170","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,12,1]]}}}